Lite Strategy, Inc. Share Price

Lite Strategy, Inc. Share Price

NASDAQ: LITS | Micro Cap
$1.20
-$0.02 (-1.64%) Last updated on 29 Oct, 2026 | 21:00 IST
  • Performance
  • Chart
  • Fundamentals
  • Quarterly P&L
  • Annual P&L
  • About
  • Price history
  • FAQs

Lite Strategy, Inc. Stock Performance

Open
$1.19
Prev. Close
$1.22
Circuit Range
N/A
Day Range
$1.19 - $1.20
Year Range
$0.69 - $2.25
Volume
11,238
Average Traded
$1.19

Lite Strategy, Inc. Share Price Today

As of 29 October 2026, Lite Strategy, Inc.'s share price is $1.20. The stock opened at $1.19, compared to its previous close of $1.22. During today's trading session, Lite Strategy, Inc.'s share price traded between $1.19 and $1.20, with an average price of $1.19. Over the past 52 weeks, the stock has recorded a high of $2.25 and a low of $0.69. In terms of performance, Lite Strategy, Inc.'s share price has risen by 3.90% over the last six months and is down 42.31% on a year-on-year basis.

Lite Strategy, Inc. Share Price Chart

Line chart of the Lite Strategy, Inc. price trend over the selected period. The price fell overall, ranging from 1.19 to 1.20, ending at 1.20.
$1.19$1.20
L
Show Current Price
H

Lite Strategy, Inc. Stock Fundamentals & Key Indicators

Market Cap
$8.00M
PE Ratio (TTM)
N/A
Dividend Yield
0.00%
EPS (TTM)
$-2.34
Revenue (TTM)
$0.00
Return On Equity (TTM)
-170.94%
Profit Margin
N/A
Debt to Equity
0.00
Quarterly Earnings Growth YoY
-257.69%

Lite Strategy, Inc. Quarterly Profit & Loss

All figures in USD

ParticularsSep 2025Dec 2025Mar 2026Jun 2026
Revenue$0.00$0.00$0.00$0.00
Net Profit-$3.64-$30.80-$23.69-$13.02
Net Profit MarginN/AN/AN/AN/A
Income ChangeN/A-746.15%23.08%45.04%

Lite Strategy, Inc. Annual Profit & Loss

All figures in USD

Particulars2026
Revenue$0.00
Net Profit-$71.15
Net Profit MarginN/A
Income ChangeN/A

About Lite Strategy, Inc.

Lite Strategy Inc is focused on the clinical development of novel therapies for cancer. The company's portfolio of drug candidates includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor, and zandelisib, an oral, once-daily, selective PI3K inhibitor. It is a clinical-stage pharmaceutical company committed to the development of novel and differentiated cancer therapies intended to improve outcomes for patients. The company operates in the segments: Digital Asset Treasury Strategy and Development of Pharmaceutical Products.

Lite Strategy, Inc. Historical Returns

Share price history by day, with open and close prices and the day's change
MonthOpenCloseChange %
Oct 2026
$1.29
$1.19
-9.85%
Sep 2026
$0.98
$1.32
+30.69%
Aug 2026
$0.98
$1.01
+5.87%
Jul 2026
$0.95
$0.95
+2.36%
Jun 2026
$0.97
$0.93
-7.17%
May 2026
$1.15
$1.00
-13.07%
Apr 2026
$1.15
$1.16
+0.87%
Mar 2026
$1.10
$1.15
+0.44%
Feb 2026
$1.21
$1.14
-5.79%
Jan 2026
$1.46
$1.21
-9.70%
Dec 2025
$1.73
$1.34
-29.10%
Nov 2025
$2.06
$1.89
-9.13%

LITS Share Price FAQs